Sehr geehrte Leser, haben Sie gewusst, dass es seit über 70 Jahren bei der Behandlung von Diabetes-Patienten keine bahnbrechenden Entwicklungen mehr gab?Patienten müssen sich Insulin spritzen und kontinuierlich ihren Blutzuckerspiegel ...
LONDON, ONTARIO - TheNewswire - July 3, 2019 - Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF), a clinical-stage regenerative medicine company today announced that in an interim analysis of its human Phase I/II clinical trial, Sernova's Cell Pouch transplanted with islet cells showed initial safety, as well as key efficacy measures, including glucose-stimulated C-peptide, insulin production and additional clinically significant measures of glucose control in the first study patient with type-1 diabetes and severe hypoglycemia unawareness. Dr. Piotr Witkowski, Director of Pancreatic, and Islet Transplant Program at the University of Chicago and study principal investigator presented on Sernova's Cell Pouch technology and preliminary data from Sernova's current clinical trial: A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch for Clinical Islet Transplantation today at the 17th World Congress of the International Pancreas and Islet Transplantation Association (IPITA) in Lyon, France. Highlights of the presentation of the data from the first patient who received islet transplanted into Sernova Cell Pouch included:- No incidences of adverse events determined to be related to the Cell Pouch implant.- The Cell Pouch was well-incorporated with vascularized tissue, which enabled successful transplant of the purified islets- A weight reduction of 6.35kg (12% total body weight)- Stabilizing improvements in all glycemic control parameters as indicated by Continuous Glucose Monitoring (CGM) as assessed by Medtronic- 87.5% reduction in hypoglycemic events from baseline collected over a two-week monitoring period- Presence of stimulated blood levels of C-peptide and insulin at the observed 90-day post-transplant point as indicated in a mixed meal tolerance test "I am quite pleased with these interim results in the first implanted patient," said Dr. Witkowski. "The first of two doses of islets transplanted into the Cell Pouch is showing safety and early indicators of efficacy. Importantly, demonstration of glucose-stimulated C-peptide and insulin present in the bloodstream is definitive proof of islet survival and function in the Cell Pouch. These results are an important first step towards a paradigm shift in the treatment of this debilitating disease. Our team is looking forward to reporting longer-term results in enrolled patients as the trial progresses," said Dr. Witkowski, principal study investigator.
ORIGINAL: Sernova to Present Clinical Validation of the Cell Pouch as a Viable, Safe Site for Diabetes Cell Therapy at the American Diabetes Association's Virtual 80th Scientific Sessions
2020-06-03 09:00 ET - News Release
LONDON, ONTARIO - TheNewswire - June 3, 2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH ), a clinical-stage regenerative medicine therapeutics company, is pleased to announce that its submitted abstract entitled "Clinical Validation of the Implanted Pre-Vascularized Cell Pouch as a Viable, Safe Site for Diabetes Cell Therapy" has been selected for presentation at the upcoming American Diabetes Association's (ADA) Virtual 80 th Scientific Sessions to be held June 12-16, 2020. Sernova's presentation (ePoster 205-LB) will be available to conference attendees beginning June 13, 2020, at 11:00 am EDT.
"We are pleased to have the opportunity to present these scientific results at the ADA's Virtual 80th Scientific Sessions," said Dr. Philip Toleikis, President and CEO of Sernova.
All information contained in the submitted abstract should be considered preliminary and subject to change until the study is fully presented at the 80th Scientific Sessions. All information is subject to embargo until June 13, 2020, at 11:00 am EDT.
Entscheidender dürfte die Präsentation über die Ergebnisse der aktuellen Studien zum Cell Pouch bei dem Kongress der ADA gewesen sein, die ja im Vorfeld als Geheimnis gehütet und heute dort ab 11 Uhr veröffentlicht wurde. Kennt da jemand ein Ergebnis?
Sernova hebt positive Ergebnisse hervor, die auf den virtuellen 80. wissenschaftlichen Sitzungen der American Diabetes Association vorgestellt wurden. https://www.sernova.com/press/release/?id=282 Klingt doch vielversprechend!